DrugPatentWatch Database Preview

Onyx Therap Company Profile

ONYX THERAP has one approved drug.

There are eleven US patents protecting ONYX THERAP drugs.

There are one hundred and seventy patent family members on ONYX THERAP drugs in thirty-six countries and nine supplementary protection certificates in eight countries.

International Patents:	170
US Patents:	11
Tradenames:	1
Ingredients:	1
NDAs:	1
Patent Litigation for Onyx Therap:	See patent lawsuits for Onyx Therap

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012		RX	Yes	Yes	8,207,127	➤ Sign Up				➤ Sign Up
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012		RX	Yes	Yes	9,511,109	➤ Sign Up				➤ Sign Up
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-002	Jun 3, 2016		RX	Yes	No	8,207,126	➤ Sign Up	Y			➤ Sign Up
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012		RX	Yes	Yes	9,493,582	➤ Sign Up	Y			➤ Sign Up
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-002	Jun 3, 2016		RX	Yes	No		➤ Sign Up				➤ Sign Up
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012		RX	Yes	Yes	8,129,346	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Injection	10 mg/vial	➤ Subscribe	2018-11-28
➤ Subscribe	For Injection	60 mg/vial	➤ Subscribe	2016-07-20

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
European Patent Office	2564834	➤ Sign Up
Eurasian Patent Organization	201690276	➤ Sign Up
Israel	214776	➤ Sign Up
Russian Federation	2014136206	➤ Sign Up
Israel	217211	➤ Sign Up
European Patent Office	2270026	➤ Sign Up
Colombia	6361942	➤ Sign Up
Country	Document Number	Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0805	Netherlands	➤ Sign Up	PRODUCT NAME: CARFILZOMIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/15/1060 20151123
2016 00014	Denmark	➤ Sign Up	PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1060 20151123
0160008 00189	Estonia	➤ Sign Up	PRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015
90013-6	Sweden	➤ Sign Up	PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/15/1060 20151123
015	Luxembourg	➤ Sign Up	PRODUCT NAME: CARFILZOMIB EVENTUELLEMENT SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151123
C0017	France	➤ Sign Up	PRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: EU/1/15/1060 20151123
16/013	Ireland	➤ Sign Up	PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/15/1060 20151119
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.